Friday 6 November 2026 Export LGND’s income statement to Excel — free account

Ligand Pharmaceuticals Incorporated

LGND Healthcare Biotechnology

Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.

Revenue: −31.8%
EPS: −123.8%
Free cash flow: −268.5%
Total debt: +153.3%

Quarter to September 2026, against a year earlier

306.43 7.43 +2.48%

Follow LGND

Alert me

Market cap: $6.0B
P/E: 118×
Fwd P/E: 88.3×
Dividend yield: —
F-score: 6/9
Altman Z: 5.45
Beneish M: −4.02
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Ligand Pharmaceuticals Incorporated 10-K filed Feb 28, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed Feb 28, 2025 · accepted 4:02 PM ET · Document on sec.gov · Filing index

Red flags

Material weakness Feb 28, 2025
Ligand Pharmaceuticals Incorporated’s 10-K reports a material weakness in internal control over financial reporting

Our implementation of our remediating plans for the material weakness, described above, resulted in changes in our internal control over financial reporting.

10-K filed Feb 28, 2025 · The filing · sec.gov